Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

5-FU is named as an intervention in 88 current clinical trials in our China, USA, Japan, Italy, Germany, Canada, Mexico, South Korea, Taiwan, France, Spain, UK, Israel, Australia, Netherlands, Poland, Brazil, Norway, Turkey, Czechia, Denmark, Belgium, Switzerland, Sweden, Egypt, Portugal, Singapore, India and Austria registers. 50 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (8). The most-studied condition is Colorectal Cancer.

Trials by status

Recruiting5057%
Not yet open78%
Active, closed3135%

Trials by phase

Phase 33034%
Phase 23034%
Phase 1/21315%
Phase 1910%
Phase 2/333%
Not applicable22%
Phase 411%

Clinical trials of 5-FU

88 trials

Study	Phase	Status	Lead sponsor	Registers
Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis NCT06499415 · ClinicalTrials.gov ↗ · Actinic Keratoses	Phase 4	Recruiting	Maastricht University Medical Center	Netherlands
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer NCT02535221 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Peking University	China
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver NCT02885753 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Recruiting	Federation Francophone de Cancerologie Digestive	France, Belgium
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC NCT03303495 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms	Phase 3	Recruiting	Sun Yat-sen University	China
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) NCT04447352 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Krankenhaus Nordwest	Germany
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer NCT04495088 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Ralf Hofheinz	Germany
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma NCT04997837 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fudan University	China
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) NCT05008809 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Dominik Paul Modest	Germany
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma NCT05677490 · ClinicalTrials.gov ↗ · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer NCT06509126 · ClinicalTrials.gov ↗ · Colorectal Cancer Stage IV	Phase 3	Recruiting	National Cancer Institute, Naples	Italy
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. NCT06733038 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. NCT06897644 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Advanced or Metastatic	Phase 3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400 · ClinicalTrials.gov ↗ · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	BeOne Medicines	UK, USA, China, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Brazil, Mexico, Japan, South Korea
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial NCT07271355 · ClinicalTrials.gov ↗ · Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum	Phase 3	Recruiting	City of Hope Medical Center	Egypt
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer NCT07673887 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	USA, Japan
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients NCT06280495 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 2/3	Recruiting	Sun Yat-sen University	China
Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery NCT04452461 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma	Phase 2	Recruiting	Hamilton Health Sciences Corporation	Canada
ATATcH Alternating Treatment Plans for Advanced Cancer NCT05358548 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Lung Cancer	Phase 2	Recruiting	Rutgers, The State University of New Jersey	Israel
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) NCT05472259 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	Recruiting	Belgian Group of Digestive Oncology	Belgium
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico, Israel, Egypt
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Poland, Canada, Japan, South Korea, Taiwan, Singapore, Australia
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer NCT06341296 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	West China Hospital	China
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607 · ClinicalTrials.gov ↗ · Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Germany, Italy, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma NCT06632717 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	National Taiwan University Hospital	Taiwan
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial NCT06770582 · ClinicalTrials.gov ↗ · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma NCT07018570 · ClinicalTrials.gov ↗ · Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Recruiting	National Cancer Center Hospital East	Japan
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma NCT07069712 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Italy, Poland, Turkey, Canada, Japan, Taiwan
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer NCT07150247 · ClinicalTrials.gov ↗ · BRAF V600 Colorectal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer NCT07474727 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Multitude Therapeutics Inc	China
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07484724 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States NCT07554521 · ClinicalTrials.gov ↗ · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	BeOne Medicines	USA
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma NCT07700667 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC NCT07733180 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	BeOne Medicines	Japan
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · ClinicalTrials.gov ↗ · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Spain, Italy, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Norway, Brazil, South Korea, Taiwan
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China, Australia
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Czechia, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV NCT06782685 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancer (Part 1)	Phase 1/2	Recruiting	Dai, Guanghai	China
AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma	Phase 1/2	Recruiting	Akeso	China
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer NCT07056777 · ClinicalTrials.gov ↗ · Gastrointestinal Cancer	Phase 1/2	Recruiting	Zhejiang Doer Biologics Co., Ltd	China
A Study of YL242 in Subjects With Advanced Solid Tumors NCT07197827 · Advanced Solid Tumor	Phase 1/2	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd	USA, China, Australia
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors NCT07256782 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Qilu Pharmaceutical Co., Ltd	China
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China, France, Spain, Netherlands, Sweden, Canada, Japan, Israel
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer NCT06825624 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer NCT06856447 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Recruiting	toqa saad mohammed mohammed	Egypt
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer NCT07024615 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays NCT07283939 · ClinicalTrials.gov ↗ · Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile	Not applicable	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC NCT05780294 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Leucogen, Chemotherapy	Phase 3	Not yet open	Sun Yat-sen University	China
Pre-Operative Treatment in REseCTable COlon CanceR NCT06899477 · ClinicalTrials.gov ↗ · Colo-rectal Cancer, Colon Cancer, Colon Carcinoma	Phase 3	Not yet open	Dominik Paul Modest	Germany
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer NCT07472868 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Carcinoma	Phase 3	Not yet open	J. W. A. Burger	Netherlands
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC NCT06648525 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Not yet open	Harbin Medical University	China
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC NCT06684158 · ClinicalTrials.gov ↗ · GC/GEJC	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment NCT06370754 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Not yet open	Fudan University	China
NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer NCT07314385 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Metastatic, Liver Metastasis	Phase 1	Not yet open	National Taiwan University Hospital	Taiwan
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT00588770 · ClinicalTrials.gov ↗ · Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair NCT02912559 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome	Phase 3	Active, closed	National Cancer Institute (NCI)	Germany, Mexico, Israel
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study NCT02997228 · ClinicalTrials.gov ↗ · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT NCT03340896 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 3	Active, closed	Groupe Oncologie Radiotherapie Tete et Cou	France
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer NCT03775265 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) NCT04241185 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Portugal, Turkey, Japan, South Korea, Taiwan, Australia, Israel
Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients NCT04246684 · ClinicalTrials.gov ↗ · Rectal Cancer Stage III	Phase 3	Active, closed	Prof. Dr. med. Claus Rödel	Germany
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer NCT04607421 · Neoplasms	Phase 3	Active, closed	Pfizer	UK, USA, India, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB NCT04776655 · ClinicalTrials.gov ↗ · Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation	Phase 3	Active, closed	Azienda USL Reggio Emilia - IRCCS	Italy
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) NCT05239741 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Nordic Pancreatic Cancer Trial (NorPACT) - 1 NCT02919787 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2/3	Active, closed	Oslo University Hospital	Sweden, Denmark, Norway
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery NCT04068103 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8	Phase 2/3	Active, closed	NRG Oncology	Canada, Mexico
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness NCT03421288 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany, Switzerland
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study NCT04166318 · ClinicalTrials.gov ↗ · Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial NCT04216290 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. NCT04229459 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Baruch Brenner	Israel
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread NCT04233866 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Germany, Spain, Italy, Netherlands, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) NCT05564403 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer NCT05843188 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Active, closed	University Health Network, Toronto	Canada
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc	USA, Germany, France, Spain
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas NCT06557889 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 2	Active, closed	Institut Claudius Regaud	France
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Active, closed	Genmab	UK, USA, China, Germany, France, Spain, Italy, Denmark, South Korea, Taiwan, Israel
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer NCT04821284 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8	Phase 1/2	Active, closed	Flemming Forsberg	Norway
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors NCT03872947 · ClinicalTrials.gov ↗ · Solid Tumor, Colorectal Cancer, Cholangiocarcinoma	Phase 1	Active, closed	Toray Industries, Inc	USA, France
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) NCT05464030 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Active, closed	EMD Serono Research & Development Institute, Inc	USA, Spain, Canada, Japan, South Korea
First in Human Study of AZD9592 in Solid Tumors NCT05647122 · ClinicalTrials.gov ↗ · Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms	Phase 1	Active, closed	AstraZeneca	USA, China, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Australia
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer NCT06547385 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma NCT03306901 · ClinicalTrials.gov ↗ · Esophageal Cancer	Not applicable	Active, closed	Samsung Medical Center	South Korea

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with 5-FU

143 conditions

Colorectal Cancer10 Colorectal Neoplasms5 Gastric Cancer5 Pancreatic Ductal Adenocarcinoma4 Esophageal Squamous Cell Carcinoma4 Gastroesophageal Junction Adenocarcinoma3 Metastatic Colorectal Cancer3Gastroesophageal Adenocarcinoma2Biliary Tract Cancer2 Advanced Solid Tumor2 Advanced Solid Tumors2Gastroesophageal Junction (GEJ) Adenocarcinoma2

All 143 conditions

Condition (as registered)	Trials
Colorectal Cancer	10
Colorectal Neoplasms	5
Gastric Cancer	5
Pancreatic Ductal Adenocarcinoma	4
Esophageal Squamous Cell Carcinoma	4
Gastroesophageal Junction Adenocarcinoma	3
Metastatic Colorectal Cancer	3
Gastroesophageal Adenocarcinoma	2
Biliary Tract Cancer	2
Advanced Solid Tumor	2
Advanced Solid Tumors	2
Gastroesophageal Junction (GEJ) Adenocarcinoma	2
Esophageal Cancer	2
Pancreatic Cancer	2
Advanced Esophageal Squamous Cell Carcinoma	2
Colon Adenocarcinoma	2
Colon Carcinoma	2
Metastatic Pancreatic Ductal Adenocarcinoma	2
Stage II Pancreatic Cancer AJCC v8	2
Bladder Urothelial Carcinoma	2
Stage IV Pancreatic Cancer AJCC v8	2
Malignant Solid Tumor	1
Non-Small Cell Lung Cancer (NSCLC)	1
Colorectal Cancer (CRC)	1
Melanoma	1
Neoplasms	1
Carcinoma, Non-Small-Cell Lung	1
Stomach Neoplasms	1
Urinary Bladder Neoplasms	1
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer	1
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer	1
Metastatic Gastric Adenocarcinoma or Cancer	1
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)	1
Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)	1
Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Gastroesophageal Junction Cancer	1
Metastatic Gastric Adenocarcinoma	1
Gastric Adenocarcinoma	1
Advanced Unresectable Gastric Adenocarcinoma	1
Advanced Gastroesophageal Adenocarcinoma	1
Gastroesophageal Junction	1
Esophageal Neoplasms	1
Solid Tumor	1
Cholangiocarcinoma	1
Bladder Cancer	1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer	1
Esophageal Adenocarcinoma	1
Esophageal Squamous Cell Cancer	1
Siewert Type 1 GEJ Cancer	1
Advanced Solid Tumours	1
Carcinoma Non-small Cell Lung	1
Head and Neck Neoplasms	1
Nasopharyngeal Carcinoma	1
Leucogen	1
Chemotherapy	1
Myelosuppression	1
Liver Metastases	1
Gastrointestinal Cancer	1
Breast Cancer	1
Advanced Pancreatic Cancer (Part 1)	1
Neoplasm Metastasis	1
Intestinal Neoplasms	1
Gastrointestinal Neoplasms	1
Non-small Cell Lung Cancer Stage IIIB/IV	1
Head and Neck Squamous Cell Carcinoma (HNSCC)	1
Colorectal Adenocarcinoma	1
Intrahepatic Cholangiocarcinoma (Icc)	1
Metastatic Colorectal Cancer (CRC)	1
BRAF V600 Colorectal Cancer	1
GC/GEJC	1
Solid Cancer	1
HER2-positive Gastric Cancer	1
Metastatic Gastric Cancer	1
Unresectable Gastric Carcinoma	1
Rectal Cancer Stage III	1
Rectal Cancer	1
DNA Repair Disorder	1
Lynch Syndrome	1
Stage III Colon Cancer AJCC v8	1
Colo-rectal Cancer	1
Colon Cancer	1
Head and Neck Squamous Cell Carcinoma	1
Squamous Cell Carcinoma of Head and Neck	1
RAS Mutation	1
Colorectal Cancer Stage IV	1
Pancreatic Adenocarcinoma Advanced or Metastatic	1
Actinic Keratoses	1
Locally Advanced Rectal Carcinoma	1
Locally Advanced Pancreatic Ductal Adenocarcinoma	1
Stage IIA Pancreatic Cancer AJCC v8	1
Muscle Invasive Bladder Carcinoma	1
Stage II Bladder Cancer AJCC v8	1
Stage IIIA Bladder Cancer AJCC v8	1
Stage IIA Colon Cancer AJCC v8	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Hepatoblastoma	1
Pancreatic Adenocarcinoma	1
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma	1
Stage III Pancreatic Cancer AJCC v8	1
Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Stage I Bladder Cancer AJCC v8	1
Anal Basaloid Carcinoma	1
Anal Canal Cloacogenic Carcinoma	1
Anal Canal Squamous Cell Carcinoma	1
Anal Margin Squamous Cell Carcinoma	1
Metastatic Colorectal Adenocarcinoma	1
Stage IV Colorectal Cancer AJCC v7	1
Advanced Biliary Tract Carcinoma	1
Advanced Gallbladder Carcinoma	1
Advanced Intrahepatic Cholangiocarcinoma	1
Recurrent Biliary Tract Carcinoma	1
Stage III Bladder Cancer AJCC v8	1
Advanced Malignant Solid Neoplasm	1
Anatomic Stage III Breast Cancer AJCC v8	1
Anatomic Stage IV Breast Cancer AJCC v8	1
Locally Advanced Malignant Solid Neoplasm	1
Neck Squamous Cell Carcinoma of Unknown Primary	1
Recurrent Hypopharyngeal Squamous Cell Carcinoma	1
Recurrent Laryngeal Squamous Cell Carcinoma	1
Recurrent Laryngeal Verrucous Carcinoma	1
Advanced Esophageal Adenocarcinoma	1
Advanced Gastric Adenocarcinoma	1
Advanced Gastroesophageal Junction Adenocarcinoma	1
Clinical Stage III Esophageal Adenocarcinoma AJCC v8	1
Ampulla of Vater Carcinoma	1
Appendix Carcinoma	1
Carcinoma of Unknown Primary With Gastrointestinal Profile	1
Metastatic Pancreatic Adenocarcinoma	1
Metastatic Esophageal Squamous Cell Carcinoma	1
Pancreatic Adenocarcinoma Metastatic	1
Liver Metastasis	1
Hepatocellular Carcinoma	1
Head and Neck Cancer	1
Lung Cancer	1
Metastatic Appendix Carcinoma	1
Metastatic Colorectal Carcinoma	1
Metastatic Malignant Neoplasm in the Peritoneum	1
Stage IV Appendix Carcinoma AJCC v8	1

By country register

Register	Trials	Recruiting
Clinical trials in China	36	26
Clinical trials in USA	22	14
Clinical trials in Japan	17	11
Clinical trials in Italy	16	10
Clinical trials in Germany	15	7
Clinical trials in Canada	15	8
Clinical trials in Mexico	15	5
Clinical trials in South Korea	14	7
Clinical trials in Taiwan	14	8
Clinical trials in France	13	6
Clinical trials in Spain	13	6
Clinical trials in UK	11	7
Clinical trials in Israel	10	3
Clinical trials in Australia	10	6
Clinical trials in Netherlands	7	3
Clinical trials in Poland	7	4
Clinical trials in Brazil	7	5
Clinical trials in Norway	6	2
Clinical trials in Turkey	6	5
Clinical trials in Czechia	5	3
Clinical trials in Denmark	4	0
Clinical trials in Belgium	4	3
Clinical trials in Switzerland	4	3
Clinical trials in Sweden	3	1
Clinical trials in Egypt	3	3
Clinical trials in Portugal	2	1
Clinical trials in Singapore	2	2
Clinical trials in India	1	0
Clinical trials in Austria	1	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about 5-FU trials

How many clinical trials are testing 5-FU?

88 current trials in our China, USA, Japan, Italy, Germany, Canada, Mexico, South Korea, Taiwan, France, Spain, UK, Israel, Australia, Netherlands, Poland, Brazil, Norway, Turkey, Czechia, Denmark, Belgium, Switzerland, Sweden, Egypt, Portugal, Singapore, India and Austria registers name 5-FU as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are 5-FU trials recruiting patients?

Yes. 50 of the 88 trials are recruiting: 26 with sites in China, 14 with sites in USA, 11 with sites in Japan, 10 with sites in Italy, 7 with sites in Germany, 8 with sites in Canada, 5 with sites in Mexico, 7 with sites in South Korea, 8 with sites in Taiwan, 6 with sites in France, 6 with sites in Spain, 7 with sites in UK, 3 with sites in Israel, 6 with sites in Australia, 3 with sites in Netherlands, 4 with sites in Poland, 5 with sites in Brazil, 2 with sites in Norway, 5 with sites in Turkey, 3 with sites in Czechia, 3 with sites in Belgium, 3 with sites in Switzerland, 1 with sites in Sweden, 3 with sites in Egypt, 1 with sites in Portugal, 2 with sites in Singapore and 1 with sites in Austria. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors 5-FU clinical trials?

National Cancer Institute (NCI) (8), Merck Sharp & Dohme LLC (5), AstraZeneca (5) and Sun Yat-sen University (4), among 59 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how 5-FU works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how 5-FU works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists 5-FU (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

5-FU clinical trials